AR075436A1 - Produccion y purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina - Google Patents

Produccion y purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina

Info

Publication number
AR075436A1
AR075436A1 ARP100100441A ARP100100441A AR075436A1 AR 075436 A1 AR075436 A1 AR 075436A1 AR P100100441 A ARP100100441 A AR P100100441A AR P100100441 A ARP100100441 A AR P100100441A AR 075436 A1 AR075436 A1 AR 075436A1
Authority
AR
Argentina
Prior art keywords
piperazine
dimethylphenylsulfanyl
phenyl
hbr
solution
Prior art date
Application number
ARP100100441A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR075436A1 publication Critical patent/AR075436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Reivindicacion 1: Un proceso para la produccion de de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina o su sal aceptable para uso farmacéutico que comprende el paso de obtener una solucion disolviendo la sal 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr en un solvente que comprende más del 65% (v/v) de isopropanol. Reivindicacion 15: El proceso de acuerdo con la reivindicacion 1 que comprende el paso de a) obtener, una solucion disolviendo 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr en un solvente que comprende más del 65% (v/v) de isopropanol; b) precipitar isopropanol solvato de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr a partir de dicha solucion obtenida; c) disolver isopropanol solvato de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr en un solvente que no forma solvatos; y d) precipitar 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr a partir de la solucion obtenida en c). Reivindicacion 19: Un proceso para eliminar o reducir una impureza de la sal 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr solida o una solucion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr, comprendiendo el proceso los pasos de: a) mezclar un solvente que comprende más del 65% (v/v) de isopropanol con 1-2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr o con una solucion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr para obtener una solucion de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr; y b) enfriar dicha solucion obtenida para precipitar isopropanol solvato de 1-(2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr isopropanol solvato; c) disolver isopropanol solvato de 1-[2-(2,4-dimetilfenilsulfanil) fenil]piperazina-HBr, en un solvente que no forma solvatos; y d) precipitar 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr a partir de la solucion que se obtuvo en el paso c). Reivindicacion 22: Un compuestos que es isopropanol solvato de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina-HBr.
ARP100100441A 2009-02-17 2010-02-16 Produccion y purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina AR075436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900223 2009-02-17

Publications (1)

Publication Number Publication Date
AR075436A1 true AR075436A1 (es) 2011-03-30

Family

ID=42101395

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100441A AR075436A1 (es) 2009-02-17 2010-02-16 Produccion y purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina

Country Status (28)

Country Link
US (1) US8598348B2 (es)
EP (1) EP2398785B1 (es)
JP (1) JP5738774B2 (es)
KR (1) KR101639833B1 (es)
CN (1) CN102317272B (es)
AR (1) AR075436A1 (es)
AU (1) AU2010214956B2 (es)
BR (1) BRPI1006975B1 (es)
CA (1) CA2751498C (es)
CL (1) CL2011001992A1 (es)
CO (1) CO6400224A2 (es)
DK (1) DK2398785T3 (es)
EA (1) EA020473B1 (es)
ES (1) ES2441079T3 (es)
HK (1) HK1165955A1 (es)
HR (1) HRP20131236T1 (es)
IL (1) IL214178A (es)
MX (1) MX2011008661A (es)
NZ (1) NZ594658A (es)
PL (1) PL2398785T3 (es)
PT (1) PT2398785E (es)
RS (1) RS53074B (es)
SG (1) SG173735A1 (es)
SI (1) SI2398785T1 (es)
SM (1) SMT201400010B (es)
TW (1) TW201033181A (es)
WO (1) WO2010094285A1 (es)
ZA (1) ZA201105992B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012364402B2 (en) 2012-01-03 2016-10-06 H. Lundbeck A/S Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
WO2014044721A1 (en) 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
CN104853755B (zh) 2012-12-13 2017-08-22 H.隆德贝克有限公司 包含沃替西汀和多奈哌齐的组合物
MX362355B (es) * 2013-02-22 2019-01-14 H Lundbeck As Proceso de fabricacion de vortioxetina.
US20160200698A1 (en) * 2013-09-12 2016-07-14 Hangzhou Pushai Pharmaceutical Technology Co., Ltd Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
IN2013MU03121A (es) 2013-09-30 2015-07-17 Cadila Healthcare Ltd
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN103788020B (zh) * 2014-01-22 2015-11-04 苏州明锐医药科技有限公司 沃替西汀的制备方法
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
CN105669594A (zh) * 2014-11-19 2016-06-15 康普药业股份有限公司 抗抑郁症药1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪的制备方法
CN105801517A (zh) * 2014-12-30 2016-07-27 上海奥博生物医药技术有限公司 一种沃替西汀氢溴酸盐新晶型及其制备方法
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN105439980B (zh) * 2015-05-08 2017-10-24 北京北陆药业股份有限公司 一种氢溴酸沃替西汀一仲丁醇合物及其制备方法
CN105367515B (zh) * 2015-05-08 2017-10-27 北京北陆药业股份有限公司 一种氢溴酸沃替西汀α晶型的制备方法
CN106316985B (zh) * 2015-06-18 2021-11-09 郑州深蓝海生物医药科技有限公司 一种β型高效氢溴酸沃替西汀转晶方法
WO2017125504A1 (en) * 2016-01-20 2017-07-27 Amneal Pharmaceuticals Company Gmbh Polymorphic forms of vortioxetine hydrobromide tert-butanolate
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
HRP20220108T1 (hr) * 2017-04-25 2022-04-15 H. Lundbeck A/S Postupak za proizvodnju vortioksetina hbr alfa-oblika
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
CN112125868B (zh) * 2020-09-25 2021-08-03 中山万远新药研发有限公司 一种氢溴酸伏硫西汀晶型及其制备方法、组合物与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852974A (en) 1958-04-17 1960-11-02 Parke Davis & Co Ethers and means for producing the same
FR2186237B1 (es) 1972-05-03 1975-10-31 Synthelabo
US5576460A (en) 1994-07-27 1996-11-19 Massachusetts Institute Of Technology Preparation of arylamines
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PL2044043T5 (pl) * 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine

Also Published As

Publication number Publication date
JP2012517961A (ja) 2012-08-09
CA2751498C (en) 2017-09-12
SMT201400010B (it) 2014-03-07
AU2010214956B2 (en) 2012-08-23
JP5738774B2 (ja) 2015-06-24
US20120004409A1 (en) 2012-01-05
BRPI1006975B1 (pt) 2022-11-22
US8598348B2 (en) 2013-12-03
IL214178A (en) 2014-09-30
AU2010214956A1 (en) 2011-09-22
HK1165955A1 (en) 2012-10-12
NZ594658A (en) 2013-02-22
CL2011001992A1 (es) 2012-04-09
TW201033181A (en) 2010-09-16
IL214178A0 (en) 2011-08-31
EP2398785B1 (en) 2013-11-27
SG173735A1 (en) 2011-09-29
MX2011008661A (es) 2011-09-06
DK2398785T3 (da) 2013-12-16
WO2010094285A1 (en) 2010-08-26
RS53074B (en) 2014-04-30
EA020473B1 (ru) 2014-11-28
CO6400224A2 (es) 2012-03-15
CN102317272A (zh) 2012-01-11
BRPI1006975A2 (pt) 2020-08-18
EP2398785A1 (en) 2011-12-28
HRP20131236T1 (hr) 2014-02-14
CN102317272B (zh) 2014-11-12
KR101639833B1 (ko) 2016-07-14
ZA201105992B (en) 2012-10-31
PL2398785T3 (pl) 2014-07-31
PT2398785E (pt) 2013-12-26
CA2751498A1 (en) 2010-08-26
EA201171065A1 (ru) 2012-02-28
ES2441079T3 (es) 2014-01-31
SI2398785T1 (sl) 2014-01-31
KR20110126625A (ko) 2011-11-23

Similar Documents

Publication Publication Date Title
AR075436A1 (es) Produccion y purificacion de 1-[2-(2,4-dimetilfenilsulfanil)fenil] piperazina
ES2568009T3 (es) Procedimiento para la absorción de CO2 a partir de una mezcla gaseosa con un medio de absorción que contiene aminas
AR081332A1 (es) Procedimiento para extraer petroleo usando tensioactivos basados en una mezcla de alcoxilatos de alquilo que contienen radicales guerbet c32, guerbet c34 y guerbet c36.
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
CL2009000771A1 (es) Proceso para preparar una suspensión de la sal del ácido metanosulfónico de etexilato de dabigatran en talco e hidroxipropilcelulosa en isopropoanol a 30 grados; la suspensión que se obtiene; su uso para preparar pellets de dicho metanosulfonato; y los pellets que se obtienen
RS52542B (en) NEW PROCEDURE FOR THE SYNTHESIS OF IVABRADINE AND ITS ADDITIONAL SALTS WITH PHARMACEUTICALLY ACCEPTABLE ACID
BR112013028487A2 (pt) inibidores do vírus da hepatite c
ECSP13012438A (es) Proceso para preparar compuestos antivirales
ECSP099708A (es) Nuevos métodos
AR106955A1 (es) Sistemas y métodos para mejorar la recuperación de co-productos a partir de granos y/o componentes de grano utilizados para producción bioquímica y/o de biocombustible utilizando agentes que rompan la emulsión
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
EA201000147A1 (ru) Способ выделения и очистки монтелукаста
BR112014009222A8 (pt) processos para a preparação de novos derivados de benzimidazol
ES2571043T3 (es) Preparación de dihidropiridinas
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
CO2020006258A2 (es) Proceso para preparar partículas de isoxazolina de gran tamaño
ES2650247T3 (es) Procedimiento de preparación del bosentán
CR20110524A (es) Proceso para preparar compuestos antivirales
AR073640A1 (es) Metodo para obtener un drivado aminoindan mesilato
WO2014013465A3 (en) Salts and hydrates of antipsychotics
AR104145A1 (es) Método de producción de epirrubicina, intermediario y sal farmacéutica
AR103821A1 (es) Un método para separar compuestos de un caldo de fermentación
NI201200141A (es) Hidrato del hidrobromuro de agomelatina y preparación de éste
PE20141794A1 (es) N-(3-{[(3-{[2-cloro-5-(metoxi)fenil]amino}quinoxalin-2-il)amino]sulfonil}fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
AR077456A1 (es) Elaboracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1il)-1,2,2- trimetil- piperazina y 1-((1r,3s)-6-cloro-3- fenil-indan-1-il-) -3,3-dimetil- piperazina

Legal Events

Date Code Title Description
FC Refusal